2005 Cohort Review, Indices for Contact Investigation	1st Qtr	2nd Qtr	3rd Qtr	Year-to-Date
Total Number of TB disease cases	23	27	20	70
	17/22	20/26	11/20	48/68
TB disease cases on DOT	77.3%	76.9%	55.0%	70.6%
Number of TB disease cases the died before completion of				
therapy	3 4		3	10
Number of Pulmonary TB disease cases	18	15	15	48
Number of Smear positive TB disease cases		8	8	26
Percent of Smear positive TB disease cases with >0 contacts	10/10	8/8	8/8	26/26
identified	100.0%	100.0%	100.0%	100.0%
Smear positive contacts identified	704	155	939	1798
Smear positive contacts appropriate for evaluation	587	137	262	986
Smear positive contacts evaluated	452	130	186	768
	452/587	130/137	186/262	768/986
Percent of smear positive contacts evaluated	77.0%	94.9%	71.0%	77.9%
Smear positive contacts started on LTBI treatment	33	21	37	91
Smear positive contacts completed LBTI treatment	8	8	11	27
Smear positive contacts still taking meds for LTBI	20	13	18	51
	28/33	21/21	29/37	78/91
Smear positive contacts expected to complete LTBI treatment	84.8%	100.0%	78.4%	85.7%
# MDR cases		0	0	1
Rif resistant / intolerant and still on therapy		1	0	2
	12/23	16/27	13/20	41/70
TB disease preventable case rate	52.2%	59.3%	65.0%	58.6%

2005 Cohort Review, Selected Treatment Variables	1st Qtr	2nd Qtr	3rd Qtr	Year-to-Date
Number of TB disease cases	23	27	20	70
Number of TB disease cases reported at death	1	1	0	2
TB disease cases that died during treatment	3	2	3	8
TB disease cases MDR and still on treatment	0	0	0	0
TB disease cases rifampin resistant / intolerant and still on				
therapy		1	0	2
Percent of TB disease cases that completed an ATS/CDC				
regiment in <12 months (for whom therapy for one year or less	10/18	16/22	12/17	38/57
is indicated)	55.6%	72.7%	70.6%	66.7%
Percent of TB cases likely to complete, plus those that have completed the above regimen		22/22	16/17	55/57
		100.0%	94.1%	96.5%
	01/18	00/24	01/17	02/59
Cohort failure(s)	5.6%	0.0%	5.9%	3.4%
Percent of Pulmonary TB cases sputum smear (+) that have	08/10			
sputum specimens collected weekly (no less than 8 hrs apart) until 3 consecutive smears are negative		06/07	07/08	
		85.7%	87.5%	84.0%
Percent of Pulmonary TB cases sputum smear (+) or sputum culture (+) that have documented sputum culture conversion				
by two months, collected on consecutive days each month		06/07	07/08	21/25
until 3 cultures are (-).		85.7%	87.5%	84.0%
	17/22	20/26	11/17	48/65
Percent of TB cases on DOT	77.3%	76.9%	64.7%	73.8%

2005 Cohort Review, Selected Program Variables	1st Qtr	2nd Qtr	3rd Qtr	Year-to-Date
Total Number of TB disease cases	23	27	20	70
	15/22	19/26	13/20	47/68
TB disease cases interviewed within 3 business days	68.2%	73.1%	65.0%	69.1%
	17/23	15/27	14/20	46/70
Percent of RVCTs submitted within 21 days	73.9%	55.6%	70.0%	65.7%
Class A, B1/B2 Immigrants/Refugees evaluated for TB within 30 days of arrival in MO		09/16	12/19	30/49
		56.3%	63.2%	61.2%
Percent of TB disease cases started on an ATS/CDC	17/22	26/26	19/19	62/67
regiment within 1 month of diagnosis	77.3%	100.0%	100.0%	92.5%
Percent of TB specimens submitted for NAA testing that were				
reported <= 48 hrs of receipt at SPHL (Mt. Vernon) =	19/21	26/28	09/15	54/64
laboratory confirmation	90.5%	92.9%	60.0%	84.4%

2005 Cohort Review, Select Epi Variables	1st Qtr	2nd Qtr	3rd Qtr	Year-to-Date
Total Number of TB disease cases	23	27	20	70
Number of Pulmonary TB disease cases	18	15	15	48
Number of smear positive TB disease cases	10	8	8	26
Number of Extrapulmonary TB disease cases	5	12	5	22
Age range all cases	15-92	19-90	05-95	15-92
Average age all cases	48	48	89	48
	13/23	17/27	15/20	45/70
Percent Male	56.5%	63.0%	75.0%	64.3%
	10/23	10/27	06/20	26/70
Percent Female	43.5%	37.0%	30.0%	37.1%
	08/09	06/10	3/3	17/22
Known HIV status of TB disease cases in 25-44 age group	88.9%	60.0%	100.0%	77.3%
	14/23	14/27	11/20	39/70
Known HIV status of all TB disease cases	60.9%	51.9%	55.0%	55.7%
	07/23	06/27	04/20	17/70
Percent of TB disease cases not offered HIV testing	30.4%	22.2%	20.0%	24.3%
	00/23	03/27	00/20	03/70
Percent of TB disease cases co-infected with HIV	0.0%	11.1%	0.0%	4.3%
	12/23	16/27	13/20	41/70
Percent of preventable TB disease cases	52.2%	59.3%	65.0%	58.6%

2005 Cohort Review, Indices as they related					
to TB Elimination Grant Objectives	1st Qtr	2nd Qtr	3rd Qtr	Year-to-Date	Grant Objectives
D					
Percent of TB cases that complete an ATS/CDC	40/40	40/00	40/47	00/57	
regiment in <12 months (for whom therapy for	10/18	16/22	12/17	38/57	. = 0 /
one year or less is indicated	55.6%	72.7%	70.6%	66.7%	95%
	4-440	00/00	4044-		†
Percent of TB cases likely to complete, plus	17/18	22/22	16/17	55/57	l l
those that have completed the above regimen	94.4%	100.0%	94.1%	96.5%	
	10/10	8/8	8/8	26/26	
Smear positive cases with >0 contacts identified	100.0%	100.0%	100.0%	100.0%	100%
	452/587	130/137	186/262	768/986	
Smear positive contacts evaluated	77.0%	94.9%	71.0%	77.9%	95%
Smear positive contacts completed LTBI	00/22	06/17	11/37	17/76	
treatment	0.0%	35.3%	29.7%	22.4%	85%
					A
Smear positive contacts expected to complete,	28/33	21/21	29/37	78/91	
plus those that have completed LTBI treatment	84.8%	100.0%	78.4%	85.7%	
Class A, B1/B2 Immigrants/Refugees evaluated	09/14	09/16	14/21	30/49	
for TB within 30 days of arrival in MO	64.3%	56.3%	63.2%	61.2%	90%
TB case rate in US Born African Americans	0.1	0.6	1	1.1	<5 per 100,000
	08/09	06/10	3/3	17/22	-
Known HIV status for age group 25-44	88.9%	60.0%	100.0%	77.3%	90%
RVCT Completeness	92.0%	96.0%	97.9%	95.0%	95%
Develop of all laboratory confirmed TD that					
Percent of all laboratory confirmed TB cases that	00/04	20/44	00/45	E0/77	
occurred within 48 hours of specimen receipt	09/21	32/41	09/15	50/77	
<healthy 2010="" goal="" people=""></healthy>	42.9%	78.0%	60.0%	64.9%	75%